Key result
Interruption of antiplatelet therapy after treatment of in-stent restenosis with drug-eluting stents was associated with late stent thrombosis and ST elevation myocardial infarction in three cases.
Case Report (n=3)
Interruption of antiplatelet therapy after treating in-stent restenosis with drug-eluting stents may carry a significant risk of late stent thrombosis and STEMI.
May warrant caution interrupting antiplatelet therapy after DES for ISR; case reports leave optimal duration open for prospective study.
Drug-eluting stent usage has become commonplace for the percutaneous treatment of de novo coronary lesions, but the safety and efficacy profile for their evolving usage in restenotic lesions is largely unknown. We report three cases of angiographically confirmed drug-eluting stent thrombosis following treatment of restenotic lesions that occurred late (193, 237, and 535 days) and shortly after interruption of antiplatelet therapy. All three patients suffered ST elevation myocardial infarction, and there was one death. Further studies are necessary to better define the associated risk and ideal duration of antiplatelet therapy necessary in this cohort of patients with restenotic lesions.
No takes yet. Share an insight, caveat, or question.
Waters et al. (2005) conducted a case report in In-stent restenosis treated with drug-eluting stents (n=3). Interruption of antiplatelet therapy after drug-eluting stent placement for restenosis was evaluated on Stent thrombosis and ST elevation myocardial infarction. Interruption of antiplatelet therapy after treatment of in-stent restenosis with drug-eluting stents was associated with late stent thrombosis and ST elevation myocardial infarction in three cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: